This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Fast track cell, gene & car-t commercialization from concept to robust patient-centric delivery.

Allogeneic and Autologous Cell Therapies Survey 2021

Share this article

As more cell therapy programs emerge and mature, there is also plenty of opportunity for innovation between development processes for allogeneic and autologous products. While each model has its own benefits, risks and limitations, how do companies choose which is right for their programs, and refine processes and technologies accordingly?

In association with Catalent, Cell & Gene Therapy Manufacturing & Commercialization is conducting a global survey to find out the state of allogeneic and autologous product development in the cell therapy space. The final report will reveal the biggest trends and challenges in research and manufacturing between both product types.

Click here to take part in the survey.

Share this article

Upcoming event

Cell & Gene Therapy Manufacturing & Commercialization Asia

11 - 14 Apr 2022, Presented in Japan Standard Time (JST)
The ONLY Cell and Gene Therapy event in Asia to help you fast track manufacturing & commercialization across borders
Go to site